Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Detection of colonic dysplasia in patients with ulcerative colitis using a targeted fluorescent peptide and confocal laser endomicroscopy: A pilot study.

De Palma GD, Colavita I, Zambrano G, Giglio MC, Maione F, Luglio G, Sarnelli G, Rispo A, Schettino P, D'Armiento FP, De Palma FDE, D'Argenio V, Salvatore F.

PLoS One. 2017 Jun 30;12(6):e0180509. doi: 10.1371/journal.pone.0180509. eCollection 2017.

2.

Host defense peptide-derived privileged scaffolds for anti-infective drug discovery.

Nigro E, Colavita I, Sarnataro D, Scudiero O, Daniele A, Salvatore F, Pessi A.

J Pept Sci. 2017 Apr;23(4):303-310. doi: 10.1002/psc.2962. Epub 2017 Jan 12.

PMID:
28078813
3.

An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule.

Nigro E, Colavita I, Sarnataro D, Scudiero O, Zambrano G, Granata V, Daniele A, Carotenuto A, Galdiero S, Folliero V, Galdiero M, Urbanowicz RA, Ball JK, Salvatore F, Pessi A.

Sci Rep. 2015 Dec 21;5:18450. doi: 10.1038/srep18450.

4.

Design and activity of a cyclic mini-β-defensin analog: a novel antimicrobial tool.

Scudiero O, Nigro E, Cantisani M, Colavita I, Leone M, Mercurio FA, Galdiero M, Pessi A, Daniele A, Salvatore F, Galdiero S.

Int J Nanomedicine. 2015 Oct 15;10:6523-39. doi: 10.2147/IJN.S89610. eCollection 2015.

5.

Membrane protein 4F2/CD98 is a cell surface receptor involved in the internalization and trafficking of human β-Defensin 3 in epithelial cells.

Colavita I, Nigro E, Sarnataro D, Scudiero O, Granata V, Daniele A, Zagari A, Pessi A, Salvatore F.

Chem Biol. 2015 Feb 19;22(2):217-28. doi: 10.1016/j.chembiol.2014.11.020. Epub 2015 Jan 29.

6.

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.

Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, Pane F.

Leuk Res. 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. Epub 2013 Nov 15.

PMID:
24280282
7.

Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells.

Colavita I, Esposito N, Quintarelli C, Nigro E, Pane F, Ruoppolo M, Salvatore F.

Proteomics. 2013 Aug;13(16):2414-8. doi: 10.1002/pmic.201200444. Epub 2013 Jul 16.

8.

The secretome signature of colon cancer cell lines.

Imperlini E, Colavita I, Caterino M, Mirabelli P, Pagnozzi D, Del Vecchio L, Di Noto R, Ruoppolo M, Orrù S.

J Cell Biochem. 2013 Nov;114(11):2577-87. doi: 10.1002/jcb.24600.

PMID:
23744648
9.

Chimeric beta-defensin analogs, including the novel 3NI analog, display salt-resistant antimicrobial activity and lack toxicity in human epithelial cell lines.

Scudiero O, Galdiero S, Nigro E, Del Vecchio L, Di Noto R, Cantisani M, Colavita I, Galdiero M, Cassiman JJ, Daniele A, Pedone C, Salvatore F.

Antimicrob Agents Chemother. 2013 Apr;57(4):1701-8. doi: 10.1128/AAC.00934-12. Epub 2013 Jan 28.

10.

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.

Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F.

Blood. 2011 Sep 29;118(13):3634-44. doi: 10.1182/blood-2011-03-341073. Epub 2011 Aug 5.

11.

Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.

Colavita I, Esposito N, Martinelli R, Catanzano F, Melo JV, Pane F, Ruoppolo M, Salvatore F.

Biochim Biophys Acta. 2010 Oct;1804(10):1974-87. doi: 10.1016/j.bbapap.2010.04.009. Epub 2010 Apr 24.

PMID:
20417730

Supplemental Content

Loading ...
Support Center